Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical Trial

by NASDAQ Market News September 10, 2020

NASDAQ Market News
Click here to email author

Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) Amyloidosis

Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer

Ads